BR112018006674A2 - method of treating disorders associated with the melanocortin-4 receptor pathway - Google Patents

method of treating disorders associated with the melanocortin-4 receptor pathway

Info

Publication number
BR112018006674A2
BR112018006674A2 BR112018006674-5A BR112018006674A BR112018006674A2 BR 112018006674 A2 BR112018006674 A2 BR 112018006674A2 BR 112018006674 A BR112018006674 A BR 112018006674A BR 112018006674 A2 BR112018006674 A2 BR 112018006674A2
Authority
BR
Brazil
Prior art keywords
subject
mutation
agonist
gene
arg
Prior art date
Application number
BR112018006674-5A
Other languages
English (en)
Portuguese (pt)
Inventor
H.T. Van Der Ploeg Leonardus
Henderson Bart
Kuhnen Peter
Original Assignee
Charité-Universitätsmedizin Berlin
Rhythm Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charité-Universitätsmedizin Berlin, Rhythm Pharmaceuticals, Inc. filed Critical Charité-Universitätsmedizin Berlin
Publication of BR112018006674A2 publication Critical patent/BR112018006674A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112018006674-5A 2015-09-30 2016-09-29 method of treating disorders associated with the melanocortin-4 receptor pathway BR112018006674A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562235003P 2015-09-30 2015-09-30
US62/235,003 2015-09-30
PCT/US2016/054457 WO2017059076A1 (en) 2015-09-30 2016-09-29 Method of treating melanocortin-4 receptor pathway-associated disorders

Publications (1)

Publication Number Publication Date
BR112018006674A2 true BR112018006674A2 (en) 2018-10-09

Family

ID=57138146

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018006674-5A BR112018006674A2 (en) 2015-09-30 2016-09-29 method of treating disorders associated with the melanocortin-4 receptor pathway

Country Status (20)

Country Link
US (5) US20180215790A1 (https=)
EP (5) EP4360704A3 (https=)
JP (8) JP6940853B2 (https=)
KR (1) KR20180063221A (https=)
CN (2) CN108431023B (https=)
AU (6) AU2016330773A1 (https=)
BR (1) BR112018006674A2 (https=)
CA (2) CA3000673A1 (https=)
DK (1) DK3356386T3 (https=)
ES (1) ES2985734T3 (https=)
FI (1) FI3356386T3 (https=)
HK (1) HK1259424A1 (https=)
IL (3) IL299541A (https=)
MA (2) MA43040A (https=)
MX (2) MX2018003983A (https=)
PL (1) PL3356386T3 (https=)
PT (1) PT3356386T (https=)
SG (1) SG10202101510XA (https=)
WO (2) WO2017059076A1 (https=)
ZA (1) ZA201802704B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2862444A1 (en) 2011-12-29 2013-07-04 Rhythm Metabolic, Inc. Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
MA43040A (fr) * 2015-09-30 2018-08-08 Univ Berlin Charite Méthode de traitement de troubles associés à la voie du récepteur de la mélanocortine 4
BR112020009648A2 (pt) * 2017-11-15 2020-11-10 Rhythm Pharmaceuticals, Inc. formulações peptídicas de liberação prolongada
CA3090966A1 (en) 2018-02-20 2019-08-29 Charite - Universitatsmedizin Berlin Mc4r agonist efficacy in subjects with mc4r deficiencies and impaired nfat signaling
WO2019219714A1 (en) 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
CN108841932B (zh) * 2018-07-13 2021-03-12 东北农业大学 一种预示和鉴定鸡腹部脂肪量的分子标记方法及应用
WO2021225972A1 (en) * 2020-05-04 2021-11-11 Regeneron Pharmaceuticals, Inc. Proprotein convertase subtilisin/kexin type 1 (pcsk1) variants and uses thereof
EP4216979A4 (en) * 2020-09-24 2024-11-06 Rhythm Pharmaceuticals, Inc. Methods of treating melanocortin-4 receptor pathway-associated disorders
JP2024532294A (ja) * 2021-08-24 2024-09-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｍｃ４ｒアゴニストペプチド
EP4605077A1 (en) 2022-10-18 2025-08-27 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
EP4618952A2 (en) * 2022-11-18 2025-09-24 Rhythm Pharmaceuticals, Inc. Methods for treating obesity with an mc4r agonist
WO2024155828A1 (en) * 2023-01-18 2024-07-25 Loma Linda University Health Uses of aminopyridines in the management of weight and satiety
CN118530299B (zh) * 2023-08-25 2025-02-07 广州益养生物科技有限公司 一种三肽、三肽盐或衍生物及其应用
WO2026022136A1 (en) * 2024-07-23 2026-01-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5226895A (en) 1989-06-05 1993-07-13 Eli Lilly And Company Multiple dose injection pen
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU1860697A (en) 1995-09-08 1997-07-28 Visionary Medical Products Corporation Pen-type injector drive mechanism
US5688251A (en) 1995-09-19 1997-11-18 Becton Dickinson And Company Cartridge loading and priming mechanism for a pen injector
US6603058B1 (en) 1998-12-09 2003-08-05 Oklahoma Medical Research Foundation Non-human animal model for obesity and uses thereof
US20030144174A1 (en) 1998-12-09 2003-07-31 Miles B. Brennan Methods for identifying compounds useful for the regulation of body weight and associated conditions
US7319107B2 (en) 2001-11-08 2008-01-15 Johnson & Johnson Consumer Companies, Inc. 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
DE10251673A1 (de) 2001-11-09 2003-07-10 Hoffmann La Roche Alström-Syndrom-Gen, Genvarianten, codiertes Protein und Verfahren zur Diagnose des Alström-Syndroms
US20060147936A1 (en) 2003-02-19 2006-07-06 Ulrich Frey Use of a gene mutation in the human gnas gene for predicting risks of diseases, courses of the disease and for predicting the response to disease therapies
GB0304822D0 (en) 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
EP1617832B1 (en) 2003-04-29 2008-03-12 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
CA2530024A1 (en) 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(mc4) agonists and their uses
US7910101B2 (en) 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
PL2286825T3 (pl) 2005-07-08 2017-06-30 Ipsen Pharma Ligandy receptora melanokortyny
JP2009500426A (ja) 2005-07-08 2009-01-08 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス メラノコルチン受容体のリガンド
US8247530B2 (en) 2005-11-08 2012-08-21 Palatin Technologies, Inc. N-alkylated cyclic peptide melanocortin agonists
US8114844B2 (en) 2006-03-30 2012-02-14 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptidomimetics
EP2106405A2 (en) 2007-01-18 2009-10-07 Novo Nordisk A/S Peptides for use in the treatment of obesity
WO2008087187A1 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
JP2010516654A (ja) 2007-01-18 2010-05-20 ノボ・ノルデイスク・エー／エス 肥満の治療に使用される新規ペプチド
WO2008087188A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
EP1974729A1 (en) 2007-03-28 2008-10-01 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists
ES2618315T3 (es) 2007-05-25 2017-06-21 Ipsen Pharma S.A.S. Ligandos del receptor de melanocortina modificados con hidantoína
EP2019100A1 (en) 2007-07-19 2009-01-28 Santhera Pharmaceuticals (Schweiz) AG Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
TW201002340A (en) 2008-06-09 2010-01-16 Palatin Technologies Inc Melanocortin receptor-specific peptides for treatment of obesity
KR101687037B1 (ko) 2008-06-09 2016-12-15 팔라틴 테크놀로지스 인코포레이티드 성기능 장애 치료용 멜라노코르틴 수용체-특이적 펩티드
JP5530438B2 (ja) 2008-08-06 2014-06-25 ファイザー・リミテッド Ｍｃ４作動薬としてのジアゼピンおよびジアゾカン化合物
US8563742B2 (en) 2008-08-29 2013-10-22 High Point Pharmaceuticals, Llc Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use
US9393369B2 (en) 2008-09-15 2016-07-19 Medimop Medical Projects Ltd. Stabilized pen injector
EP2168965A1 (en) 2008-09-25 2010-03-31 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine, imidazopyrazine, imidazopyridazine and imidazopyrimidine derivatives as melanocortin-4 receptor antagonists
WO2010037081A1 (en) 2008-09-29 2010-04-01 Palatin Technologies, Inc. Melanocortin receptor-specific spiro-piperidine compounds
FR2937973B1 (fr) 2008-11-04 2010-11-05 Galderma Res & Dev Modulateurs des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
FR2937868B1 (fr) 2008-11-04 2010-11-05 Galderma Res & Dev Composes antagonistes des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
UA99555C2 (en) 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
JP2012509862A (ja) 2008-11-25 2012-04-26 ノヴォ・ノルディスク・アー／エス 肥満の治療のためのペプチド
WO2010065802A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Substituted pyrrolidine or imidazolidine melanocortin receptor-specific compounds
WO2010065801A1 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperazine melanocortin receptor-specific compounds
WO2010065800A1 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Hydrazine substituted piperidine melanocortin receptor-specific compounds
WO2010065799A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperidine melanocortin receptor-specific compounds
EP2210885A1 (en) 2009-01-14 2010-07-28 Santhera Pharmaceuticals (Schweiz) AG Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
WO2010096854A1 (en) 2009-02-27 2010-09-02 Mimetica Pty Ltd Methods of modulating the activity of the mc3 and/or mc4 receptors and treatment of conditions related to these receptors
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
KR101726893B1 (ko) * 2009-06-08 2017-04-13 팔라틴 테크놀로지스 인코포레이티드 멜라노코르틴 수용체-특이적 펩티드
BR112012002445A2 (pt) 2009-08-05 2015-10-13 Ipsen Pharma Sas uso de um agonista do receptor 4 de melanocortina.
CN102574894A (zh) 2009-08-31 2012-07-11 张力控制股份有限公司 稳定化的黑皮质素配体
US9314509B2 (en) 2009-11-16 2016-04-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
EP2539364A1 (en) 2010-02-26 2013-01-02 Novo Nordisk A/S Peptides for treatment of obesity
CA2862444A1 (en) * 2011-12-29 2013-07-04 Rhythm Metabolic, Inc. Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
RU2020120797A (ru) 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
PL2970389T3 (pl) 2013-03-15 2021-03-08 Rhythm Pharmaceuticals, Inc. Kompozycje farmaceutyczne
MA43040A (fr) 2015-09-30 2018-08-08 Univ Berlin Charite Méthode de traitement de troubles associés à la voie du récepteur de la mélanocortine 4

Also Published As

Publication number Publication date
IL299541A (en) 2023-02-01
IL258412B2 (en) 2023-06-01
US20180311309A1 (en) 2018-11-01
DK3356386T3 (da) 2024-05-21
AU2023229494A1 (en) 2023-09-28
JP2021102650A (ja) 2021-07-15
IL289996B1 (en) 2023-03-01
US20220226425A1 (en) 2022-07-21
JP2023078335A (ja) 2023-06-06
MA43038A (fr) 2018-08-08
CN108431023A (zh) 2018-08-21
CN108601816A (zh) 2018-09-28
WO2017059076A1 (en) 2017-04-06
EP4029513A1 (en) 2022-07-20
CA3000670A1 (en) 2017-04-06
IL289996B2 (en) 2023-07-01
HK1259424A1 (zh) 2019-11-29
MX2023003358A (es) 2023-03-29
JP6940853B2 (ja) 2021-09-29
EP3355905A1 (en) 2018-08-08
PL3356386T3 (pl) 2024-08-05
KR20180063221A (ko) 2018-06-11
US20180215790A1 (en) 2018-08-02
SG10202101510XA (en) 2021-03-30
US10960046B2 (en) 2021-03-30
CN108431023B (zh) 2022-11-04
PT3356386T (pt) 2024-05-17
FI3356386T3 (fi) 2024-05-16
EP4711004A2 (en) 2026-03-18
US20250195606A1 (en) 2025-06-19
ZA201802704B (en) 2024-08-28
EP3356386A1 (en) 2018-08-08
JP2018531938A (ja) 2018-11-01
WO2017059076A8 (en) 2018-04-26
US20210169970A1 (en) 2021-06-10
EP3356386B1 (en) 2024-02-14
ES2985734T3 (es) 2024-11-07
US12263202B2 (en) 2025-04-01
IL289996A (en) 2022-03-01
EP4360704A3 (en) 2024-07-24
AU2016330773A1 (en) 2018-04-19
MX2018003983A (es) 2018-11-09
AU2016330772A1 (en) 2018-04-19
MA43040A (fr) 2018-08-08
WO2017059075A1 (en) 2017-04-06
AU2024278597A1 (en) 2025-01-16
EP4360704A2 (en) 2024-05-01
AU2021201448A1 (en) 2021-03-25
JP7752373B2 (ja) 2025-10-10
JP2022173426A (ja) 2022-11-18
IL258412A (en) 2018-05-31
JP2026042856A (ja) 2026-03-11
AU2022279420A1 (en) 2023-01-19
CA3000673A1 (en) 2017-04-06
JP2025019234A (ja) 2025-02-06
AU2022279420B2 (en) 2024-09-19
JP2021088611A (ja) 2021-06-10
JP2018531937A (ja) 2018-11-01
JP7051106B2 (ja) 2022-04-11

Similar Documents

Publication Publication Date Title
US20250195606A1 (en) Method of treating melanocortin-4 receptor pathway-associated disorders
US20180194803A1 (en) Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
US20260001915A1 (en) Methods for treating obesity with an mc4r agonist
WO2022067086A1 (en) Methods of treating melanocortin-4 receptor pathway-associated disorders
EP3755362B1 (en) Mc4r agonist efficacy in subjects with mc4r deficiencies and impaired nfat signaling
HK40077660A (en) Melanocortin-4 receptor agonists for the treatment of disorders characterised by pomc gene hypermethylation
RU2785889C1 (ru) Способ лечения нарушений, ассоциированных с путем рецептора меланокортина 4
HK40073416A (en) Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]